Halozyme Therapeutics Inc
(FRA:RV7)
€
45.9
0.41 (0.9%)
Market Cap: 5.88 Bil
Enterprise Value: 6.68 Bil
PE Ratio: 15.94
PB Ratio: 13.52
GF Score: 85/100 Halozyme Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020 / 08:40PM GMT
Release Date Price:
€21
(-0.94%)
John Hamilton DeRosa McNeil
Goldman Sachs Group Inc., Research Division - Research Analyst
All right. Hello, everyone, and welcome to day 2 of the 41st Annual Global Health Care Conference. By way of introduction, I'm Jack McNeil. I'm an associate on the U.S. SMID Biopharma and EU Biotech team, standing in for Graig Suvannavejh today.
And with us, we have Helen Torley, CEO of Halozyme Therapeutics.
So Helen, welcome back. I know you and Graig did this a year ago.
Questions & Answers
John Hamilton DeRosa McNeil
Goldman Sachs Group Inc., Research Division - Research Analyst
And I thought maybe we could talk about maybe what's changed for Halozyme in the past year. What are some of the major milestones you've hit and? What's top of mind today?
Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director
Yes. Thanks. And delighted to be back here. Thank you. Yes, 2019, I think people may be aware that in November, we got the readout of our PEGPH20 data. That was our
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot